SAB BiotherapeuticsSABS -1.81%26 OCF Yield % is -17.64 as of Jun. 27, 2026. GuruFocus rates SABS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,419 Biotechnology companies, SAB Biotherapeutics ranks worse than 65.54% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
SAB Biotherapeutics OCF Yield % Related Terms
SAB Biotherapeutics OCF Yield % Historical Data
* Premium members only.
The historical data trend for SAB Biotherapeutics's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SAB Biotherapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SAB Biotherapeutics OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SAB Biotherapeutics's OCF Yield % distribution charts can be found below:
* The bar in red indicates where SAB Biotherapeutics's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SAB Biotherapeutics (SABS) has a OCF Yield % of -17.64 as of Jun. 27, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on SAB Biotherapeutics and its competitors. According to the industry distribution chart, SAB Biotherapeutics ranks #930 out of 1419 companies in the Biotechnology industry, placing it in the top 65.5%.
Is SAB Biotherapeutics' OCF Yield % too high?
SAB Biotherapeutics' current OCF Yield % is -17.64. Based on the distribution chart, SAB Biotherapeutics ranks #930 out of 1419 companies in the Biotechnology industry, which is below the industry midpoint. Overall, SAB Biotherapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does SAB Biotherapeutics' OCF Yield % compare to TRDA and ACIU?
According to the Biotechnology industry distribution chart, SAB Biotherapeutics ranks #930 out of 1419 companies for OCF Yield %. This places SAB Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on SAB Biotherapeutics and its competitors. SAB Biotherapeutics's current OCF Yield % is -17.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SAB Biotherapeutics stock overvalued right now?
SAB Biotherapeutics (SABS) has a current OCF Yield % of -17.64. The current OCF Yield % is -17.64. SAB Biotherapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For SAB Biotherapeutics (SABS), the current OCF Yield % is -17.64 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
26GF Score
Get the complete analysis for SABS
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SABS has been successfully added to your 
